Bernstein Holds Outperform on Gilead After Arcellx Purchase; Analysts Lift Targets
Bernstein SocGen Group reaffirmed an Outperform rating and a $160 price target on Gilead Sciences after the company's acquisition of Arcellx. The transaction, valued at an implied $7.8 billion equity price, includes cash and a contingent value right tied to sales milestones and is positioned to strengthen Gilead’s CAR-T capabilities within its Kite…